Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
ZDEK: Innovator Equity Defined Protection ETF – 1 Yr December

ZDEK: Innovator Equity Defined Protection ETF – 1 Yr December

Key Takeaways

  • ZDEK is the Innovator Equity Defined Protection ETF – 1 Yr December, a "defined outcome" exchange-traded fund (ETF) issued by Innovator Capital Management.
  • The fund seeks to track the price return of the SPY (SPDR S&P 500 ETF Trust), up to an upside cap, while providing a 100% downside buffer over a one-year outcome period, before fees and expenses.
  • It is actively managed and implements its strategy using FLEX Options (customizable exchange-listed options) that reference the S&P 500, rather than holding individual stocks.
  • The fund carries a net expense ratio of 0.79%, does not distribute dividends, and resets its cap and buffer annually each December.
  • ZDEK is designed for investors seeking equity-market upside participation with built-in downside protection, not for those seeking income or traditional index exposure.

Getting to Know ZDEK

ZDEK is an exchange-traded fund (ETF) — a basket of securities that trades on an exchange like a single stock — belonging to Innovator's "Defined Outcome" lineup. Its full name is the Innovator Equity Defined Protection ETF – 1 Yr December. The fund offers a distinctive proposition: it attempts to capture a portion of U.S. large-cap equity gains while aiming to shield investors from losses over a fixed, one-year window. This structure appeals to investors who want some stock-market participation but are unwilling to accept full downside risk. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the defined-outcome space.

ETF Profile and Mechanics

ZDEK's investment objective is to track the return of the SPDR S&P 500 ETF Trust (SPY), up to a predefined upside cap, with a 100% downside buffer over a one-year outcome period, before fees and expenses. In practical terms, the fund seeks to deliver the S&P 500's price appreciation up to a ceiling, while aiming to buffer the first 100% of any losses during that same period.

Unlike a conventional index fund that buys and holds the stocks in a benchmark, ZDEK is actively managed and does not track a standard index. Instead, it invests primarily in FLEX Options (FLexible EXchange Options), which are customizable option contracts listed on an exchange that reference SPY. The fund's portfolio holdings therefore consist chiefly of options positions on the S&P 500 ETF, rather than a diversified list of individual companies.

The fund is issued by Innovator Capital Management, a firm best known for its Defined Outcome and Buffer ETF series. ZDEK was launched (inception date) in late November 2024 and listed in early December 2024 on the Cboe BZX exchange. It is a non-diversified fund, meaning it may concentrate its assets more heavily than a typical diversified ETF, and it maintains a modest number of holdings — typically only a handful of FLEX Options contracts — because the entire strategy is built around SPY-linked options.

The fund's expense ratio (the annual fee charged to shareholders as a percentage of assets) is 0.79%. It does not pay dividends or other distributions, since its objective focuses on potential price appreciation rather than income. The upside cap and downside buffer are reset each year — a process called an annual rebalance — at the start of December, which is why the fund is designated "1 Yr December." Importantly, the stated buffer and cap apply only if shares are held for the full outcome period; investors who buy or sell mid-period may experience different results.

Why Investors Follow ZDEK

ZDEK attracts attention because it addresses a common investor dilemma: how to stay invested in equities while managing the risk of a market decline. Its defined-outcome structure provides a clear, pre-stated "investment strategy" — a known upside cap and a 100% downside buffer over one year — that is rare among traditional stock funds.

The fund's sector exposure mirrors that of the S&P 500, with technology, financial services, healthcare, communication services, and consumer cyclical names historically representing the largest weightings. This means investors gain broad large-cap U.S. equity exposure, but with a hedge against losses built directly into the fund's design. For conservative investors, retirees, or those nearing a major financial goal, this buffered structure can serve as a complement to cash, Treasury securities, or market-linked certificates of deposit (CDs) within a diversified portfolio.

Risks and Important Considerations

While the downside buffer is a central selling point, several factors require attention. First, the upside cap means investors give up gains beyond a certain level; in strong market years, ZDEK will likely underperform a plain S&P 500 fund. Second, the buffer applies only over the full outcome period — buying or selling shares mid-cycle, especially after the market has already declined, can reduce or eliminate the protection.

The fund also carries market risk, the possibility that the underlying equity market declines; the buffer is not a guarantee and is stated before fees, so net returns may be slightly lower. There is tracking error risk, since FLEX Options may not perfectly mirror SPY's movements, and the fund is non-diversified, which can concentrate certain risks. The 0.79% expense ratio is higher than that of many plain index funds, and the absence of dividends means the strategy may not suit income-focused investors. Finally, FLEX Options are less liquid than standard listed options, and the fund's defined-outcome mechanics may be less suitable for short-term traders.

Conclusion

ZDEK stands out for combining large-cap U.S. equity exposure with a structured, 100% downside buffer over a defined one-year period — a profile that sets it apart from both conventional index ETFs and higher-risk strategies. Its capped upside, annual reset, and fee structure make it a specialized tool best understood as a buffered equity allocation rather than a traditional growth or income vehicle. For investors weighing the trade-off between market participation and loss protection, ZDEK remains a relevant, clearly defined option within the growing defined-outcome ETF category.

Exploring Tickeron’s AI Tools for ETF Research

In my own analysis, I often turn to Tickeron’s AI-powered platforms to screen for defined-outcome products and compare their buffers, caps, and expense ratios against peers. The AI Screener stands out for its ability to filter by technical indicators, fundamentals, volatility, and custom criteria, helping surface ideas that align with specific risk-management strategies. I’ve found it useful for building watchlists that include funds like ZDEK alongside broader market options.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ZDEK

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


ZDEK in downward trend: price dove below 50-day moving average on November 17, 2026

ZDEK moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend. In 3 of 3 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ZDEK moved out of overbought territory on October 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 1 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 4%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 3 of 29 cases where ZDEK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 10%.

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZDEK as a result. In 4 of 26 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 15%.

The Moving Average Convergence Divergence Histogram (MACD) for ZDEK turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 23 similar instances when the indicator turned negative. In 2 of the 23 cases the stock turned lower in the days that followed. This puts the odds of success at 9%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZDEK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 16%.

Bullish Trend Analysis

Following a +0.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZDEK advanced for three days, in 37 of 131 cases, the price rose further within the following month. The odds of a continued upward trend are 28%.

ZDEK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 70 of 214 cases where ZDEK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 33%.

Industry description

The investment seeks to provide investors with returns that match the upside price return of the SPDR® S&P 500® ETF Trust. The fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in FLexible EXchange® Options (“FLEX Options”) that reference the SPDR® S&P 500® ETF Trust. The fund is non-diversified.
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
CBRS fell -6.07% to $97.86 in the opening minutes of Wednesday's regular session, down from Tuesday's close of $104.18 — the move occurred during market hours, not premarket or after-hours. No verified news or fundamental catalyst found: no new filing, contract, or analyst action explains the drop, which is likely continued give-back from the post-earnings pop and the stock's habitual volatility — CBRS has averaged a ±4.5% daily swing over the past 60 sessions, and 17 of those sessions moved as much or more.
NVIDIA reported revenue of $115.84 billion for the third quarter of fiscal 2027, up 103% year over year and ahead of both company guidance and consensus estimates. Non-GAAP earnings per share (EPS, a measure of profit per outstanding share) came in at $2.68 , beating the roughly $2.47 analysts had expected.